Top Medical News
Pearl Toh, 3 hours ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
3 hours ago
Water vapour thermal therapy for lower urinary tract symptoms or benign prostatic hyperplasia does not negatively affect sexual function, a recent study has shown.
Roshini Claire Anthony, 7 hours ago

Rivaroxaban may help reduce the incidence of venous thromboembolism (VTE) and VTE-related deaths in patients who are receiving systemic treatment for metastatic malignancies, but only if they keep taking the anticoagulant, according to findings of the phase IIIb CASSINI trial.

7 hours ago
Treatment with pirfenidone may lead to significantly reduced risks of multiple progression events and death in patients with idiopathic pulmonary fibrosis, according to a study.
8 hours ago
With the exception of dipeptidyl peptidase 4 inhibitors (DPP4i), other drugs used for managing diabetes do not correlate with an elevated risk of bullous pemphigoid (BP) in a Finnish patient database, reports a recent study. This indicates that the investigated drugs can be used safely in the said population.
Stephen Padilla, 9 hours ago
A rotating night shift work and an unhealthy lifestyle can both lead to a higher risk of type 2 diabetes (T2D) among female nurses, according to a recent study. The joint effect is greater than the addition of the risks associated with a higher risk of T2D.
Jairia Dela Cruz, 10 hours ago
Obesity in children contributes to an increased risk of new physician-diagnosed asthma and asthma confirmed by pulmonary function testing, a study reports.
Special Reports
30 Nov 2018
Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.
30 Nov 2018
Poor adherence to statin therapy is leaving many patients with dyslipidaemia at high risk of potentially life-threatening cardiovascular events. Statins are the current standard of care for reducing the risk of cardiovascular disease in these patients and for improving life expectancy, with possible economic benefits for healthcare systems too. However, many patients with dyslipidaemia are not achieving or maintaining treatment targets because they fail to stick to their prescribed statin therapy. An article co-authored by lipidologist Peter Lansberg, and published in Vascular Health and Risk Management, considers this issue and reviews approaches to overcome non-adherence.
28 Nov 2018
At the recent 22nd Malaysian Conference of Psychological Medicine, Dr Hazli Zakaria spoke on the importance of early optimized treatment in improving treatment outcomes in patients with major depressive disorder (MDD).
28 Nov 2018
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
27 Nov 2018
Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
21 Nov 2018
In conjunction with the launch of Dymista® in Malaysia, Mylan convened a symposium which saw distinguished speakers addressing the allergic rhinitis (AR) landscape in the country and the latest developments in treatment options.
Conference Reports
Roshini Claire Anthony, 11 Dec 2018

The combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) more than doubled progression-free survival (PFS) as well as improved overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma compared with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to results of the phase III ECHELON-2* trial.

11 Dec 2018
Podcast: Dr Steven Horwitz highlights the ECHELON-2 findings which showed a doubled PFS with brentuximab vedotin + CHP vs CHOP in patients with CD30-expressing peripheral T-cell lymphoma.
11 Dec 2018
Podcast: Dr Ceri Bygrave explains how early relapse after stem cell transplant for myeloma is a marker of high-risk disease and a predictor of poor overall survival.
11 Dec 2018
Slideshow: Highlights from the 60th American Society of Hematology (ASH) Annual Meeting and Exposition
Elaine Soliven, 10 Dec 2018
Treatment with luspatercept, a first-in-class erythroid maturation agent, help achieves red blood cell transfusion independence (RBC-TI) in patients with anaemia who had low-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS), according to results of the MEDALIST* trial presented at ASH 2018.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Roshini Claire Anthony, 07 Dec 2018

Findings from the updated analysis of the phase III MURANO* trial solidify the role of fixed-dose venetoclax plus rituximab in a majority of patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download